FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:812-813 March 11, 1999 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Eisenberger, M. A. PubMed Citation

To the Editor: An underlying hypothesis in the study by Eisenberger et al. (Oct. 8 issue)¹ is that bilateral orchiectomy is equivalent to treatment with a gonadotropin-releasing hormone agonist (e.g., leuprolide or goserelin) in the management of advanced prostate cancer. This is probably not the case. Whereas the addition of an antiandrogen to a gonadotropin-releasing hormone agonist was beneficial in extending survival as compared with the agonist alone, a similar degree of benefit was not demonstrated when an antiandrogen was added to bilateral orchiectomy. The addition of an antiandrogen to a gonadotropin-releasing hormone agonist may address deficiencies intrinsic to this . . . [Full Text of this Article]

References

Related Letters:

Disclosure Statements Regarding Hormonal Treatment of Prostate Cancer
Garnick M. B.
Extract | Full Text  
N Engl J Med 1999; 340:1689-1690, May 27, 1999. Correspondence

This article has been cited by other articles:

• Garnick, M. B. (1999). Disclosure Statements Regarding Hormonal Treatment of Prostate Cancer. NEJM 340: 1689-1690 [Full Text]